HDGF like 1Genealiases: HRP-1 · Hdgfrp1 · PWWP1 · dJ309H15.1
Q-omics provides the consensus-scored HDGFL1 profile across patient tissues and cancer cell-line models. HDGFL1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HDGFL1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, HDGFL1 protein abundance shows 22,355 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, HNSC, and LSCC as cancer lineages where HDGFL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDGFL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDGFL1 survival associations across molecular data types. HDGFL1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDGFL1 RNA expression–survival associations across cancer types. High HDGFL1 expression shows unfavorable associations in BRCA, KICH, KIRC, CESC, LUSC and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for HDGFL1 RNA expression.
This table summarizes HDGFL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HDGFL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDGFL1 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, BRCA, LUSC and LIHC. The HNSC box plot shows higher HDGFL1 RNA expression in tumor versus normal tissue (log2 FC = +0.180, t-test p = .007).
This table shows molecular features associated with HDGFL1 in patient tissues and cancer cell lines. In patient samples, HDGFL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HDGFL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
